Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Christopher Davis, Nicola Logan, Grace Tyson, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 12, pp. e1010022-e1010022
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 533
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1161-1179
Open Access | Times Cited: 531
Impact of the Delta variant on vaccine efficacy and response strategies
Lianlian Bian, Qiushuang Gao, Fan Gao, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 10, pp. 1201-1209
Open Access | Times Cited: 215
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
Alexander C. Dowell, Megan Butler, Elizabeth Jinks, et al.
Nature Immunology (2021) Vol. 23, Iss. 1, pp. 40-49
Open Access | Times Cited: 179
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Takuya Tada, Hao Zhou, Belinda M. Dcosta, et al.
EBioMedicine (2022) Vol. 78, pp. 103944-103944
Open Access | Times Cited: 137
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Fanglei Zuo, Hassan Abolhassani, Likun Du, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 137
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 135
Virtual healthcare services and digital health technologies deployed during coronavirus disease 2019 (COVID-19) pandemic in South Africa: a systematic review
Elliot Mbunge, John Batani, Goabaone Gaobotse, et al.
Global Health Journal (2022) Vol. 6, Iss. 2, pp. 102-113
Open Access | Times Cited: 132
The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Mehrdad Mohammadi, Mohammad Shayestehpour, Hamed Mirzaei
The Brazilian Journal of Infectious Diseases (2021) Vol. 25, Iss. 4, pp. 101606-101606
Open Access | Times Cited: 125
Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 4, pp. 734-742
Open Access | Times Cited: 102
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Felicity Liew, Shubha Talwar, Andy Cross, et al.
EBioMedicine (2022) Vol. 87, pp. 104402-104402
Open Access | Times Cited: 88
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Ranjan K. Mohapatra, Ruchi Tiwari, Ashish K. Sarangi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2336-2342
Open Access | Times Cited: 82
Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Julie Perry, Selma Osman, Jim A. Wright, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266852-e0266852
Open Access | Times Cited: 79
Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
Meriem Bekliz, Kenneth Adea, Pauline Vetter, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 76
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 72
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 59
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Anu Haveri, Nina Ekström, Anna Solastie, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 12, pp. 3202-3213
Open Access | Times Cited: 90
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, et al.
EBioMedicine (2022) Vol. 83, pp. 104217-104217
Open Access | Times Cited: 62
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Ranjan K. Mohapatra, Satwik Kuppili, Tarun Kumar Suvvari, et al.
Chemical Biology & Drug Design (2022) Vol. 99, Iss. 5, pp. 769-788
Open Access | Times Cited: 58
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
Elsie Horne, William Hulme, Ruth H. Keogh, et al.
BMJ (2022), pp. e071249-e071249
Open Access | Times Cited: 54
Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma, et al.
International Journal of Biological Macromolecules (2022) Vol. 219, pp. 980-997
Open Access | Times Cited: 53
Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.
Noosha Samieefar, Ronak Rashedi, Meisam Akhlaghdoust, et al.
PubMed (2022) Vol. 93, Iss. 1, pp. e2022179-e2022179
Closed Access | Times Cited: 47
Page 1 - Next Page

Scroll to top